CNBC Television published this video item, entitled “Cramer on FDA resignations in connection with approval of Biogen’s Alzheimer’s drug” – below is their description.
UBS upgraded the Biogen’s stock to “buy” from “neutral” and Bernstein raised its rating to “outperform.” Both firms base their moves on the potential sales bump from the FDA’s approval this week of the biotech’s Alzheimer’s treatment. CNBC’s Jim Cramer, Carl Quintanilla and David Faber discuss.
CNBC Television YouTube Channel
Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.